Midterm Outcomes of Prospective, Randomized, Single-Center Study of the Janus Tacrolimus-Eluting Stent for Treatment of Native Coronary Artery Lesions

DOI:                 

Abstract

From February 20, 2006 to August 26, 2006, a total of 200 patients were enrolled and randomly assigned to receive either Janus stent (n=100) or bare metal stent (Tecnic Carbostent, n=100). All patients were administered with clopi-dogrel for 4 months and aspirin for life long after stenting. Baseline clinical and angiographic characteristics were comparable between the two groups. AMI was present in 37% of patients with Janus and 36% with Tecnic Carbostent. At an average of 246-day follow-up, major adverse cardiac events (MACE) was 6% with the Janus stent and 15% with the Tecnic Carbostent (P=0.038). Primary events included 1 cardiac death, 1 myocardial infarction (MI) due to subacute stent thrombosis and 13 target lesion revascularizations (TLR) due to restenosis in patients with Tecnic Car-bostent and 6 TLR due to restenosis in patients with Janus stent. Although all patients had discontinued clopidogrel for an average of 126 days, there was no additional thrombotic event in the two groups.

Keywords

drug-eluting stent, acute myocardial infarction, angioplasty, transluminal, percutaneous coronary

Conflicts of Interest

The authors declare no conflicts of interest.

References